Cargando…

Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma

BACKGROUND: The attenuated, genetically engineered vaccinia virus has been shown to be a promising oncolytic virus for the treatment of patients with solid tumors, through both direct cytotoxic and immune-activating effects. Whereas systemically administered oncolytic viruses can be neutralized by p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chintala, Navin K., Choe, Jennie K., McGee, Erin, Bellis, Rebecca, Saini, Jasmeen K., Banerjee, Srijita, Moreira, Andre L., Zauderer, Marjorie G., Adusumilli, Prasad S., Rusch, Valerie W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977791/ https://www.ncbi.nlm.nih.gov/pubmed/36875061 http://dx.doi.org/10.3389/fimmu.2023.1112960

Ejemplares similares

Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice
por: Offin, Michael, et al.
Publicado: (2022)

Immune responses following intrapleural administration of oncolytic SEPREHVIR in patients with malignant pleural mesothelioma
por: Learmonth, Kirsty, et al.
Publicado: (2015)

Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma
por: Branch, Kevin, et al.
Publicado: (2023)

Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy
por: Li, Xiaoyu, et al.
Publicado: (2019)

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1
por: Eguchi, Takashi, et al.
Publicado: (2017)

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma
por: Zauderer, Marjorie G.
Publicado: (2021)

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
por: Breitbach, Caroline J, et al.
Publicado: (2015)

High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
por: Delaunay, Tiphaine, et al.
Publicado: (2020)

The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study
por: Zauderer, Marjorie G, et al.
Publicado: (2021)

Theranostic Potential of Oncolytic Vaccinia Virus
por: Rojas, Juan J, et al.
Publicado: (2012)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Oncolytic properties of non-vaccinia poxviruses
por: Ricordel, Marine, et al.
Publicado: (2018)

Imaging CAR T-cell kinetics in solid tumors: Translational implications
por: Skovgard, Matthew S., et al.
Publicado: (2021)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

Oncolytic vaccinia therapy of squamous cell carcinoma
por: Yu, Zhenkun, et al.
Publicado: (2009)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
por: Truong, Cao-Sang, et al.
Publicado: (2022)

Oncolytic Viral Therapy for Mesothelioma
por: Pease, Daniel F., et al.
Publicado: (2017)

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
por: Goey, S. H., et al.
Publicado: (1995)

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T‐VEC) a first‐in‐class oncolytic viral therapy in patients with advanced melanoma
por: Ahamadi, Malidi, et al.
Publicado: (2023)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice
por: Digifico, Elisabeth, et al.
Publicado: (2020)

Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library
por: Offin, Michael, et al.
Publicado: (2022)

Targeting hematologic malignancies with oncolytic vaccinia virus constructs
por: Chen, Nanhai, et al.
Publicado: (2013)

Mapping the preclinical to clinical evidence and development trajectory of the oncolytic virus talimogene laherparepvec (T-VEC): a systematic review
por: Lalu, Manoj, et al.
Publicado: (2019)

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma
por: Ohnesorge, Paul V., et al.
Publicado: (2022)

Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
por: Myers, Rachel, et al.
Publicado: (2016)

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
por: Guo, Zong Sheng, et al.
Publicado: (2019)

An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol
por: Tada, Yuji, et al.
Publicado: (2016)

Thoracoscopy and Intrapleural Pheumonolysis: Analysis of 354 Cases
por: Nag, J. K., et al.
Publicado: (1953)

Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
por: Samson, Adel, et al.
Publicado: (2022)

Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines
por: Lee, Hyun Ju, et al.
Publicado: (2011)

Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma
por: Deng, Lili, et al.
Publicado: (2022)

Antitumor activity of recombinant oncolytic vaccinia virus with human IL2
por: Liu, Liqiong, et al.
Publicado: (2022)

Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma
por: Restle, David, et al.
Publicado: (2023)

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
por: Gallardo, Franck, et al.
Publicado: (2020)

Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
por: Chiaro, Jacopo, et al.
Publicado: (2023)

Oncolytic virotherapy for human malignant mesothelioma: recent advances
por: Boisgerault, Nicolas, et al.
Publicado: (2015)

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice
por: Gil, M, et al.
Publicado: (2011)

The intrapleural volume threshold for ultrasound detection of pneumothoraxes
por: Oveland, NP, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0dpotjn38j9ft37d5p909uvruj